ClinicalTrials.gg
RecruitingNCT06472596Updated Jun 25, 2024

Risk of Chronic Kidney Disease in Bronchial Asthma

An observational study in Bronchial Asthma, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 2 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by Sohag University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Asthma with a site in Egypt — 10 open to participants now, 11 under way, 1 of them phase 3. Asthma · Egypt.

Planned enrollment
12th of 17
100 · median 137
Started
2024
with 9 others
Observational
17 of 42
5 open now
Primary completion
2025-06
later than 1 of 10 live
Registered
25th of 42
by date
Lead sponsor
7 of 42
Sohag University

Among the 42 studies in Asthma with a site in Egypt, this one is the 12th largest by planned enrollment of the 17 observational ones that give a count, is one of 10 that started in 2024, is one of 17 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 25th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

10 of the 42 studies in Asthma with a site in Egypt are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Asthma with a site in Egypt, or all of them as a file.
02

Study summary

the study aims to determine the frequency and factors associated with chronic kidney disease among asthmatic patients in order to determine persons who are at risk of developing chronic kidney disease and require strict follow up in long run , to evaluate severity of asthma as a potential risk for developing kidney injury , to evaluate relationship between different inflammatory markers with severity of asthma and risk of deneloping chronic kidney disease

03

Conditions studied

  • Bronchial Asthma

Browse trials for

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

cases (asthmatics) and control ( healthy ) from age of 2 years to 18 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all children diagnosed as bronchial asthma at sohag university hospitals from age of 2 years to age of 18 years and donot have any associated disease

Exclusion criteria

Exclusion Criteria:

  • persons who have any chronic illness persons who have any associated disease with bronchial asthma persons who missing clinical and laboratory investigations persons who refusing to give written for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • cases ( asthmatic patients)

    asthmatics investigated by serum creatinine , GFR calculation , ESR,CRP,ABG,CBC , serum electrolytes , interleukin6, tumor necrotic factor alpha

    Diagnostic Test: CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha

  • control (healthy persons)

    healthy persons investigated by same investigations and compare results with asthmatics

    Diagnostic Test: CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha

Interventions

  • Diagnostic testCBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha

    compare results of investigations in asthmatics and non asthmatics

06

What researchers measure

Primary outcomes

  1. change in kidney function in asthmatics

    change in serum creatinine , GFR calculation

    Time frame: change in kidney function in asthmatics after diagnosis and start treatment through out the duration of study (an average 1 year )

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 12 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 25, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jul 11, 2025
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06472596
Lead sponsor
Sohag University
Responsible party
Marihan Nazmy Shehata (doctor resident at pediatric department in sohag university hospitals, Sohag University) — Principal investigator
First posted
Jun 25, 2024
Start date
Jun 1, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jul 11, 2025 (estimated)
Last update
Jun 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion